Muscle density is an independent risk factor of second hip fracture: a prospective cohort study.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
06 2022
Historique:
revised: 17 03 2022
received: 05 07 2021
accepted: 30 03 2022
pubmed: 17 4 2022
medline: 11 6 2022
entrez: 16 4 2022
Statut: ppublish

Résumé

Patients with a first hip fracture are at high risk of fracturing their other hip. Despite this, preventive therapy is often not given. Because little is known about specific risk factors of a second hip fracture, we investigated the association with areal bone mineral density (aBMD), muscle size, and density. We also investigated whether muscle parameters predict the risk of a contralateral fracture independently of aBMD. Three groups were included, one without hip fracture (a subcohort of the China Action on Spine and Hip Status study), one with a first, and one with a second hip fracture. Subjects with fractures were recruited from the longitudinal Chinese Second Hip Fracture Evaluation (CSHFE). Computed tomography scans of CSHFE patients, which were obtained immediately following their first fracture, were used to measure cross-sectional area and density of the gluteus maximus (G.MaxM) and gluteus medius and minimus (G.Med/MinM) muscles. Computed tomography X-ray absorptiometry was used to measure aBMD of the contralateral femur. Median follow-up time to second fracture was 4.5 years. Cox proportional hazards models were used to compute hazard ratios (HR) of second hip fracture risk in subjects with a first hip fracture. Multivariate logistic regressions were used to compare odds ratios (OR) for the risk of a first and second hip fracture. Three hundred and one participants (68.4 ± 6.1 years, 64% female) without and 302 participants (74.6 ± 9.9 years, 71% female) with a first hip fracture were included in the analysis. Among the latter, 45 (79.2 ± 7.1 years) sustained a second hip fracture. ORs for first hip fracture were significant for aBMD and muscle size and density. ORs for a second fracture were smaller by a factor of 3 to 4 and no longer significant for femoral neck (FN) aBMD. HRs for predicting second hip fracture confirmed the results. G.Med/MinM density (HR, 1.68; CI, 1.20-2.35) and intertrochanter aBMD (HR, 1.62; CI, 1.13-2.31) were the most significant. FN aBMD was not significant. G.Med/MinM density remained significant for predicting second hip fracture after adjustment for FN (HR, 1.66; Cl, 1.18-2.30) or total hip aBMD (HR, 1.50; 95% Cl, 1.04-2.15). Density of the G.Med/MinM muscle is an aBMD independent predictor of the risk of second hip fracture. Intertrochanteric aBMD is a better predictor of second hip fracture than FN and total hip aBMD. These results may trigger a paradigm shift in the assessment of second hip fracture risk and prevention strategies.

Sections du résumé

BACKGROUND
Patients with a first hip fracture are at high risk of fracturing their other hip. Despite this, preventive therapy is often not given. Because little is known about specific risk factors of a second hip fracture, we investigated the association with areal bone mineral density (aBMD), muscle size, and density. We also investigated whether muscle parameters predict the risk of a contralateral fracture independently of aBMD.
METHODS
Three groups were included, one without hip fracture (a subcohort of the China Action on Spine and Hip Status study), one with a first, and one with a second hip fracture. Subjects with fractures were recruited from the longitudinal Chinese Second Hip Fracture Evaluation (CSHFE). Computed tomography scans of CSHFE patients, which were obtained immediately following their first fracture, were used to measure cross-sectional area and density of the gluteus maximus (G.MaxM) and gluteus medius and minimus (G.Med/MinM) muscles. Computed tomography X-ray absorptiometry was used to measure aBMD of the contralateral femur. Median follow-up time to second fracture was 4.5 years. Cox proportional hazards models were used to compute hazard ratios (HR) of second hip fracture risk in subjects with a first hip fracture. Multivariate logistic regressions were used to compare odds ratios (OR) for the risk of a first and second hip fracture.
RESULTS
Three hundred and one participants (68.4 ± 6.1 years, 64% female) without and 302 participants (74.6 ± 9.9 years, 71% female) with a first hip fracture were included in the analysis. Among the latter, 45 (79.2 ± 7.1 years) sustained a second hip fracture. ORs for first hip fracture were significant for aBMD and muscle size and density. ORs for a second fracture were smaller by a factor of 3 to 4 and no longer significant for femoral neck (FN) aBMD. HRs for predicting second hip fracture confirmed the results. G.Med/MinM density (HR, 1.68; CI, 1.20-2.35) and intertrochanter aBMD (HR, 1.62; CI, 1.13-2.31) were the most significant. FN aBMD was not significant. G.Med/MinM density remained significant for predicting second hip fracture after adjustment for FN (HR, 1.66; Cl, 1.18-2.30) or total hip aBMD (HR, 1.50; 95% Cl, 1.04-2.15).
CONCLUSIONS
Density of the G.Med/MinM muscle is an aBMD independent predictor of the risk of second hip fracture. Intertrochanteric aBMD is a better predictor of second hip fracture than FN and total hip aBMD. These results may trigger a paradigm shift in the assessment of second hip fracture risk and prevention strategies.

Identifiants

pubmed: 35429146
doi: 10.1002/jcsm.12996
pmc: PMC9178374
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1927-1937

Subventions

Organisme : National Natural Science Foundation of China
ID : 81771831
Organisme : National Natural Science Foundation of China
ID : 81901718
Organisme : Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support
ID : ZYLX202107
Organisme : Beijing Natural Science Foundation-Haidian Primitive Innovation Joint Fund
ID : L172019

Informations de copyright

© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

JAMA Intern Med. 2021 Aug 1;181(8):1055-1063
pubmed: 34096979
Lancet. 2018 Feb 24;391(10122):741-747
pubmed: 29254858
Osteoporos Int. 2011 May;22(5):1277-88
pubmed: 21461721
J Bone Miner Res. 2010 Mar;25(3):513-9
pubmed: 20422623
J Bone Joint Surg Br. 1993 Sep;75(5):797-8
pubmed: 8376443
Osteoporos Int. 2015 Jul;26(7):1903-10
pubmed: 25910745
J Am Med Dir Assoc. 2021 Apr;22(4):751-759.e2
pubmed: 32768372
PLoS Med. 2020 Aug 6;17(8):e1003180
pubmed: 32760065
J Bone Miner Res. 2020 Jan;35(1):36-52
pubmed: 31538675
J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):485-500
pubmed: 30993881
Calcif Tissue Int. 2012 Jan;90(1):14-21
pubmed: 22076525
Endocr Pract. 2020 May;26(Suppl 1):1-46
pubmed: 32427503
J Bone Miner Res. 2000 Apr;15(4):721-39
pubmed: 10780864
Quant Imaging Med Surg. 2018 Aug;8(7):667-672
pubmed: 30211034
Arch Osteoporos. 2017 Aug 15;12(1):72
pubmed: 28812206
J Bone Miner Res. 2007 Jun;22(6):825-31
pubmed: 17352651
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2259-2261
pubmed: 34904399
Injury. 2015 Nov;46(11):2206-11
pubmed: 26298023
Radiology. 2019 Feb;290(2):426-434
pubmed: 30457478
Bone. 2012 Jun;50(6):1343-50
pubmed: 22421579
Arch Intern Med. 2007 Oct 8;167(18):1971-6
pubmed: 17923597
J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1799-1812
pubmed: 32894000
Osteoporos Int. 2020 May;31(5):921-929
pubmed: 31802158
J Gerontol A Biol Sci Med Sci. 2014 Mar;69(3):346-53
pubmed: 23873945
Eur Heart J. 2014 Nov 7;35(42):2936-41
pubmed: 24711436
Bone. 2008 Apr;42(4):798-805
pubmed: 18234578
J Cachexia Sarcopenia Muscle. 2022 Jun;13(3):1927-1937
pubmed: 35429146
Ann Intern Med. 2017 Jun 6;166(11):818-839
pubmed: 28492856
Osteoporos Int. 2016 Mar;27(3):1137-1147
pubmed: 26415934
Osteoporos Int. 2020 Oct;31(10):1817-1828
pubmed: 32613411
Bone. 2020 Oct;139:115545
pubmed: 32730940
Bone. 1997 Mar;20(3):213-8
pubmed: 9071471
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):663-677
pubmed: 32091670

Auteurs

Ling Wang (L)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.
Department of Radiology, The First People's Hospital of Yunnan Province, Kunming, China.

Lu Yin (L)

Medical Research & Biometrics Center, National Center for Cardiovascular Disease, Beijing, China.

Minghui Yang (M)

Departments of Traumatic Orthopedics, Beijing Jishuitan Hospital, Beijing, China.

Yufeng Ge (Y)

Departments of Traumatic Orthopedics, Beijing Jishuitan Hospital, Beijing, China.

Yandong Liu (Y)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Yongbin Su (Y)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Zhe Guo (Z)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Dong Yan (D)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Zhengyang Xu (Z)

Department of Radiology, the First Medical Center of Chinese PLA General Hospital, Beijing, China.

Pengju Huang (P)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Jian Geng (J)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Xingli Liu (X)

Department of Radiology, The First People's Hospital of Yunnan Province, Kunming, China.

Gang Wang (G)

Department of Radiology, The First People's Hospital of Yunnan Province, Kunming, China.

Glen M Blake (GM)

School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.

Weiming Cao (W)

Health Commission of Yunnan Province, Kunming, China.

Bo He (B)

Department of Radiology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.

Liang Lyu (L)

Department of Radiology, The First People's Hospital of Yunnan Province, Kunming, China.

Xiaoguang Cheng (X)

Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.

Xinbao Wu (X)

Departments of Traumatic Orthopedics, Beijing Jishuitan Hospital, Beijing, China.

Lihong Jiang (L)

The First People's Hospital of Yunnan Province, Kunming, China.

Annegreet Vlug (A)

Center for Bone Quality, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.

Klaus Engelke (K)

Department of Medicine 3, FAU University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Institute of Medical Physics, University of Erlangen, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH